All News

ACRmtg.jpg (keep)

EULAR 2024 – Day 3 Report

Jack Cush, MD

EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.

Read Article
heart

Matters of the heart: cardiovascular disease and mortality in RA

Mrinalini Dey, MD

Two large retrospective cohort studies presented by the team at Mayo Clinic, Rochester MN examine the burden of stroke, as well as overall and cause-specific mortality in people with RA (POS0591 and POS0592).

Read Article
RA Hands Difficult deformity

EULAR 2024 – Day 2 Report (A Difficult RA Day)

Jack Cush, MD

Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.

Read Article
RheumNow Podcast square

Is Cannabis Safe? (6.7.2024)

Jack Cush, MD

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article
medical.marijuana

Cannabis Use is Common, But is it Safe?

Jack Cush, MD

Two current JAMA reports suggest that cannabis use is not only common, but that if heavily used may increase mortality rates.

Read Article
BP.jpg

Hypertension not associated with High NSAID Doses in AxSpA

Medscape

At the recent SPARTAN annual meeting in Cleveland, Dr. Jose Meade-Aguilar reported that amongst axial spondyloarthritis patients receiving nonsteroidal anti-inflammatory drugs, there was no difference in the risk for hypertension when comparing those on high vs. low dose NSAIDs.

Read Article
RheumNow Podcast square

The Window of Opportunity (5.24.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article
POS1035 FVC & risk of lung transplant & mortality in #RAILD 50% pts had FVC % predicted decline in ~6.5yrs 2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression #EULAR2024 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

📄 You can now read my article on #CardiovascularDisease, #Stroke & #Mortality @RheumNow! 🌟 Featuring 2 cohort studies from @MayoClinic, presented at #EULAR2024 🔗 https://t.co/b639vE5hSA @MyasoedovaElena

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

#EULAR2024 OP0288 Patients with Scleroderma shouldn’t be excluded from Lung Transplantation because of a concern with post-surgery complications/long term complications. Data from Italy of N=13 pts showed 93% survival, improved disesase activity & FVC over 2 years @RheumNow https://t.co/zPFB1MFxdc

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#SARD #ILD Who to screen for #rheumatic #diseases For ILD #ACR guidelines Screening May also depend on ILD prevalence Not sure if frequency of screening and how to screen @jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6

Links:

Janet Pope Janetbirdope ( View Tweet)
Oral presentation at #EULAR2024 about clustering #RA #ILD 🫁 @PhilippeDieude @jeffsparks @RaphaelBorie @bruno_crestani https://t.co/jz1unKIZmN

Links:

PA Juge Juge_P_A ( View Tweet)
Poster tours at #EULAR2024. A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Top 3 messages Re #JAKi #safety Shared decision w benefit/risk info Some #CV risks are more Impt than others- stratify your pt into risk categories #Smoking is a big risk for #MACE & #malignancy-So work on facilitating Smoking #cessation #EULAR2024 @eular_org @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Reminder of relevance of #Rheumatoid factor ⬆️RF also predicts cardiovascular events ⚠️ ⬆️disease activity ❗️Worse outcomes #EULAR2024 #RF #RA https://t.co/kXwh682ONp

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW
Dr. John Cush RheumNow ( View Tweet)
OP0031 (2024) COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

Danish Registry study of 1.9 million chronic pain pts, shows chronic use of medicinal cannabis (5391) is assoc w/ a significant risk of new-onset arrhythmia {180d RR 2.07; 1-year RR 1.36). No significant association for acute coronary syndrome https://t.co/VT3X8lVWaD https://t.co/BMqVapFkuU

Links:

Dr. John Cush RheumNow ( View Tweet)
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study compared 5825 #AS pts vs 28,356 matched controls; showed an increased risk of pulmonary embolism w/ AS; not present pre-Dx ((0.4% vs 0.2%), but incr post-AS Dx (PE IR 11.6 vs 6.8/10KPY: adj HR 1.70;; p<0.001) https://t.co/wSkAMozvnL https://t.co/5Q470QkAxe

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×